Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms
10.1089/hum.1995.6.12-1543 · doi-reference
Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption
10.1073/pnas.92.21.9829 · doi-reference
Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7
10.1038/sj.cgt.7700003 · doi-reference
Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer
10.1038/sj.gt.3300487 · doi-reference
Inducible gene expression from defective herpes simplex virus vectors using the tetracycline-responsive promoter system
10.1016/0169-328x(96)00097-6 · doi-reference
Transcriptional activation by tetracyclines in mammalian cells
10.1126/science.7792603 · doi-reference
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
10.1073/pnas.89.12.5547 · doi-reference
Use of tetracycline-controlled gene expression systems to study mammalian cell cycle
10.1016/s0076-6879(97)83014-5 · doi-reference
Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential
10.1093/nar/25.14.2723 · doi-reference
Drug inducible transgene expression in brain using a herpes simplex virus vector
10.1038/sj.gt.3300612 · doi-reference
A regulatory system for use in gene transfer
10.1073/pnas.91.17.8180 · doi-reference
The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor
10.1016/0092-8674(92)90234-4 · doi-reference
Development of an HSV-based vector for the treatment of Parkinson's disease
10.1006/exnr.1996.6395 · doi-reference
GAL4 disrupts a repressing nucleosome during activation of GAL1 transcription in vivo
10.1101/gad.7.5.857 · doi-reference
Spatial and temporal control of gene therapy using ionizing radiation
10.1038/nm0895-786 · doi-reference
Targeting gene expression to hypoxic tumor cells
10.1038/nm0597-515 · doi-reference
Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector
10.1038/nm1097-1145 · doi-reference
Role of the retinoblastoma protein in the pathogenesis of human cancer
10.1200/jco.1997.15.11.3301 · doi-reference
Transcriptional control by E2F
10.1006/scbi.1995.0013 · doi-reference
B-myc promoter retargeting of herpes simplex virus’ γ34.5-mediated virulence towards tumor and cycling cells
10.1128/jvi.73.9.7556-7564.1999 · doi-reference
Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RLi null mutant vector-potential glioblastoma targeting
10.1038/sj.gt.3300621 · doi-reference
Structure and transcriptional regulation of the GFAP gene
10.1111/j.1750-3639.1994.tb00840.x · doi-reference
Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
10.1128/jvi.72.12.9470-9478.1998 · doi-reference
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
10.1126/science.274.5286.373 · doi-reference
Targeted gene delivery by tropism-modified adenoviral vectors
10.1038/nbt1196-1574 · doi-reference
Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob
10.1128/jvi.72.3.1844-1852.1998 · doi-reference
An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism
10.1128/jvi.72.12.9706-9713.1998 · doi-reference
Targeted adenoviral vectors for cancer gene therapy
10.1007/978-1-4615-5357-1_57 · doi-reference
Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells
10.1128/jvi.72.12.9683-9697.1998 · doi-reference
Targeting gene therapy vectors to CNS malignancies
10.3109/13550289809114514 · doi-reference
In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity
10.4049/jimmunol.160.9.4457 · doi-reference
Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector
10.1016/s0165-0270(97)00207-0 · doi-reference
Effect of exogenous nerve growth factor on neurotoxicity of and neuronal gene delivery by a herpes simplex amplicon vector in the rat brain
10.1089/hum.1994.5.8-987 · doi-reference
Herpes simplex virus vector system: analysis of its in vivo and in vitro cytopathic effects
10.1016/0165-0270(94)00150-f · doi-reference
Specific patterns of defective HSV-1 gene transfer in the adult central nervous system: implications for gene targeting
10.1006/exnr.1994.1192 · doi-reference
Introduction of a foreign gene (Escherichia coli IacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study
10.1016/0014-4886(92)90196-w · doi-reference
Nerve growth factor somatic mosaicism produced by herpes virus-directed expression of cre recombinase
10.1038/nbt0197-57 · doi-reference
Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase
10.1126/science.266.5189.1399 · doi-reference
Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia
10.1161/01.str.26.9.1670 · doi-reference
Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke
10.1097/00004647-199707000-00003 · doi-reference
